<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p61" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_61{left:130px;bottom:1196px;letter-spacing:-0.15px;}
#t2_61{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_61{left:130px;bottom:798px;letter-spacing:-0.01px;}
#t4_61{left:238px;bottom:747px;letter-spacing:-0.01px;}
#t5_61{left:238px;bottom:728px;letter-spacing:-0.01px;}
#t6_61{left:432px;bottom:728px;letter-spacing:-0.01px;}
#t7_61{left:238px;bottom:708px;letter-spacing:-0.01px;}
#t8_61{left:238px;bottom:689px;letter-spacing:-0.01px;}
#t9_61{left:238px;bottom:670px;letter-spacing:-0.01px;}
#ta_61{left:238px;bottom:650px;letter-spacing:-0.01px;}
#tb_61{left:238px;bottom:631px;letter-spacing:-0.01px;}
#tc_61{left:238px;bottom:577px;letter-spacing:-0.01px;}
#td_61{left:238px;bottom:557px;letter-spacing:-0.01px;}
#te_61{left:238px;bottom:538px;letter-spacing:-0.01px;}
#tf_61{left:238px;bottom:518px;letter-spacing:-0.01px;}
#tg_61{left:238px;bottom:499px;letter-spacing:-0.01px;}
#th_61{left:238px;bottom:479px;letter-spacing:-0.01px;}
#ti_61{left:238px;bottom:460px;letter-spacing:-0.01px;}
#tj_61{left:238px;bottom:441px;letter-spacing:-0.01px;}
#tk_61{left:238px;bottom:421px;letter-spacing:-0.01px;}
#tl_61{left:238px;bottom:402px;letter-spacing:-0.01px;}
#tm_61{left:238px;bottom:382px;letter-spacing:-0.01px;}
#tn_61{left:238px;bottom:363px;letter-spacing:-0.01px;}
#to_61{left:238px;bottom:343px;letter-spacing:-0.01px;}
#tp_61{left:238px;bottom:324px;letter-spacing:-0.01px;}
#tq_61{left:238px;bottom:304px;letter-spacing:-0.01px;}
#tr_61{left:238px;bottom:285px;letter-spacing:-0.01px;}
#ts_61{left:238px;bottom:266px;letter-spacing:-0.01px;}
#tt_61{left:238px;bottom:246px;letter-spacing:-0.01px;}
#tu_61{left:238px;bottom:153px;letter-spacing:-0.01px;}
#tv_61{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_61{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_61{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_61{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_61{font-size:13px;font-family:NotoSans-Regular_7j-_1;color:#000;}
.s4_61{font-size:11px;font-family:NotoSans-Regular_7j-_1;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts61" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

@font-face {
	font-family: NotoSans-Regular_7j-_1;
	src: url("fonts/NotoSans-Regular_7j-_1.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg61Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg61" style="-webkit-user-select: none;"><object width="908" height="1286" data="61/61.svg" type="image/svg+xml" id="pdf61" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_61" class="t s0_61">7.3. Fundamental considerations of multimodal therapy approaches </span><span id="t2_61" class="t s1_61">61 </span>
<span id="t3_61" class="t s2_61">Figure 3: Overview of standards of treatment for laryngeal carcinoma [198] </span>
<span id="t4_61" class="t s2_61">In the case of non-resectable tumors, simultaneous radiochemotherapy is considered the </span>
<span id="t5_61" class="t s2_61">standard of care if the patient's </span><span id="t6_61" class="t s3_61">general condition allows it. Simultaneous radiochemotherapy </span>
<span id="t7_61" class="t s3_61">of squamous cell carcinoma of the head and neck region has been compared with </span>
<span id="t8_61" class="t s3_61">radiotherapy alone in more than 90 randomized studies. In the meta-analysis of these studies, </span>
<span id="t9_61" class="t s3_61">which were published between 1963 and 2000, a significant absolute survival advantage of </span>
<span id="ta_61" class="t s3_61">6.5% was shown after 5 years with simultaneous radiochemotherapy compared with </span>
<span id="tb_61" class="t s3_61">radiotherapy alone [185]. </span>
<span id="tc_61" class="t s3_61">In individual studies, significantly higher survival benefits of up to 21% were reported [203, 204]. </span>
<span id="td_61" class="t s3_61">In a meta-analysis by Budach et al. [205], which only included studies with cisplatin, carboplatin, </span>
<span id="te_61" class="t s3_61">mitomycin and 5-fluorouracil, an extension of the median survival time by 12 months was </span>
<span id="tf_61" class="t s3_61">demonstrated by simultaneous chemotherapy. Blanchard et al. [186] analyzed the results of all </span>
<span id="tg_61" class="t s3_61">studies in a meta-analysis according to tumor location. In the subgroup of laryngeal carcinomas </span>
<span id="th_61" class="t s3_61">(61 studies with 3,216 patients), a survival advantage of 4.7% in favor of radiochemotherapy was </span>
<span id="ti_61" class="t s3_61">reported after 5 years. The hazard ratio 0.88 (CI 95% 0.80 - 0.96]) did not differ significantly from </span>
<span id="tj_61" class="t s3_61">that of other tumor locations in the head and neck region, so that in general, for locally </span>
<span id="tk_61" class="t s3_61">advanced head and neck tumors, simultaneous radiochemotherapy can be assumed to be </span>
<span id="tl_61" class="t s3_61">advantageous compared to radiotherapy alone. In the studies, mainly cisplatin +/- 5FU, </span>
<span id="tm_61" class="t s3_61">carboplatin +/- 5FU and mitomycin +/- 5FU were used simultaneously with radiotherapy. Since </span>
<span id="tn_61" class="t s3_61">the different chemotherapies have hardly been compared with each other in randomized </span>
<span id="to_61" class="t s3_61">studies, only indirect comparisons are possible, which suggest that cisplatin +/- 5FU has the </span>
<span id="tp_61" class="t s3_61">highest efficacy [185] and that the effect depends on the cumulative total dose of cisplatin </span>
<span id="tq_61" class="t s3_61">administered during radiotherapy [190]. Currently, the most commonly used treatments are </span>
<span id="tr_61" class="t s3_61">cisplatin 40 mg/m² once a week and cisplatin (100 mg/m² BSA) on days 1, 22 and 43 of </span>
<span id="ts_61" class="t s3_61">radiotherapy. In case of insufficient renal function, mitomycin C + 5FU [191] or carboplatin + 5FU </span>
<span id="tt_61" class="t s3_61">[193] can also be used. </span>
<span id="tu_61" class="t s3_61">Background 7.18. and 7.19. </span>
<span id="tv_61" class="t s4_61">© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
